| Title |
Targeting γ-secretase in breast cancer
|
|---|---|
| Published in |
Breast cancer targets and therapy, June 2012
|
| DOI | 10.2147/bctt.s26437 |
| Pubmed ID | |
| Authors |
Jianxun Han, Qiang Shen |
| Abstract |
γ-secretase complexes are multisubunit protease complexes that perform the intramembrane cleavage of more than 60 type-I transmembrane proteins, including Notch receptors. Since dysregulated Notch signaling has been implicated in the tumorigenesis and progression of breast cancer, small molecule γ-secretase inhibitors (GSIs) are being tested for their therapeutic potential in breast cancer treatment in several clinical trials. Here, the structure of γ-secretase complex and the development of GSIs are briefly reviewed, the roles of Notch and several other γ-secretase substrates in breast cancer are discussed, and the difference between γ-secretase inhibition and Notch inhibition, as well as the side effects associated with GSIs, are described. A better understanding of molecular mechanisms that affect the responsiveness of breast cancer to GSI might help to develop strategies to enhance the antitumor activity and, at the same time, alleviate the side effects of GSI. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| India | 1 | 33% |
| United States | 1 | 33% |
| United Kingdom | 1 | 33% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 3 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 32 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Canada | 1 | 3% |
| Unknown | 31 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 7 | 22% |
| Student > Bachelor | 6 | 19% |
| Student > Ph. D. Student | 6 | 19% |
| Student > Master | 4 | 13% |
| Other | 2 | 6% |
| Other | 2 | 6% |
| Unknown | 5 | 16% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 10 | 31% |
| Biochemistry, Genetics and Molecular Biology | 6 | 19% |
| Chemistry | 3 | 9% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 6% |
| Immunology and Microbiology | 2 | 6% |
| Other | 3 | 9% |
| Unknown | 6 | 19% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 June 2012.
All research outputs
#16,046,765
of 25,373,627 outputs
Outputs from Breast cancer targets and therapy
#155
of 324 outputs
Outputs of similar age
#108,768
of 179,216 outputs
Outputs of similar age from Breast cancer targets and therapy
#2
of 6 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. This one is in the 34th percentile – i.e., 34% of other outputs scored the same or lower than it.
So far Altmetric has tracked 324 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.0. This one is in the 47th percentile – i.e., 47% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 179,216 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 37th percentile – i.e., 37% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 6 others from the same source and published within six weeks on either side of this one. This one has scored higher than 4 of them.